Sign in

    Umer RappatEvercore ISI

    Umer Rappat's questions to Teva Pharmaceutical Industries Ltd (TEVA) leadership

    Umer Rappat's questions to Teva Pharmaceutical Industries Ltd (TEVA) leadership • Q2 2025

    Question

    Umer Rappat of Evercore ISI inquired about the expected discount range for AUSTEDO under IRA negotiations and the potential impact of newly announced European tariffs.

    Answer

    President & CEO Richard Francis stated the company would not comment on ongoing IRA negotiations with CMS. Regarding tariffs, Francis and EVP & CFO Eli Kalif explained that Teva has a flexible value chain with limited China exposure and has absorbed confirmed tariffs into its 2025 guidance, seeing no meaningful impact from the ambiguous European announcements at this time.

    Ask Fintool Equity Research AI